TRIBE2研究亚组分析:BRAF突变转移性结直肠癌中FOLFOXIRI/贝伐珠单抗获益的临床与基因表达标志物探索
该研究基于TRIBE2研究,分析46例BRAF突变转移性结直肠癌患者的临床特征和基因表达特征,以探索从一线FOLFOXIRI/贝伐珠单抗强化治疗中获益的标志物。基因表达亚型(BM1/BM2、LI/LD)与治疗获益无交互作用,但ECOG-PS>0和左侧原发肿瘤与强化治疗无获益相关。
要点
- 基因表达亚型BM1/BM2和LI/LD未能识别从FOLFOXIRI/贝伐珠单抗获益的BRAF突变mCRC患者。
- ECOG-PS>0和左侧原发肿瘤可能与强化治疗无获益相关。
- BRAF突变mCRC中FOLFOXIRI/贝伐珠单抗的获益标志物仍需进一步探索。
核心结论
- 基因表达分析未能识别出适合一线FOLFOXIRI/贝伐珠单抗治疗的BRAF突变mCRC患者。
- ECOG-PS>0和左侧原发肿瘤似乎与强化治疗无获益相关。
研究设计与样本
- TRIBE2研究的亚组分析,纳入46例BRAF突变mCRC患者的肿瘤样本进行基因表达分析。
主要发现
- 46例BRAF突变肿瘤样本中,24例(52%)为BM1亚型,22例(48%)为BM2亚型;27例(59%)为配体非依赖(LI)Wnt通路亚型,19例(41%)为配体依赖(LD)亚型。
- BM1/BM2和LI/LD亚型均无预后影响。
- BM1/BM2或LI/LD特征与FOLFOXIRI/贝伐珠单抗获益之间无交互作用。
- 无进展生存期方面,治疗组与原发性肿瘤部位之间存在显著交互作用(P=0.05),与ECOG-PS之间存在显著交互作用(P<0.001)。
临床怎么用
- 对于BRAF突变mCRC患者,ECOG-PS>0或左侧原发肿瘤可能提示不能从一线FOLFOXIRI/贝伐珠单抗强化治疗中获益。
局限性
- 样本量较小(46例BRAF突变肿瘤样本),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study. PATIENTS AND METHODS: Clinical characteristics and gene expression signatures of patients with BRAF-mutant mCRC enrolled in the TRIBE2 study were evaluated with the aim of understanding that patients may derive benefit from the intensification of the upfront chemotherapy. RESULTS: Of 46 BRAF-mutant tumour samples analysed, 24 (52%) and 22 (48%) were classified as BM1 and BM2, respectively, and 27 (59%) and 19 (41%) were assigned to ligand-independent (LI) and ligand-dependent (LD) Wnt pathway subgroups, respectively. No prognostic impact was shown for both BM1/BM2 and LI/LD subtypes. No interaction was evident between BM1/BM2 or LI/LD signatures and the benefit provided by FOLFOXIRI/bevacizumab. Significant interaction effect was evident in terms of progression-free survival between treatment arm and primary tumour sidedness (P = 0.05) and Eastern Cooperative Oncology Group performance status (ECOG-PS; P < 0.001). CONCLUSIONS: Gene expression analysis failed to identify patients with BRAF-mutant mCRC candidate to upfront FOLFOXIRI/bevacizumab. ECOG-PS >0 and left-sidedness seem associated with no benefit from the intensified treatment.
引用
- Moretto R, Giordano M, Poma AM, et al. Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. Eur J Cancer. 2021. PMID: 34126333. doi:10.1016/j.ejca.2021.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。